Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment

Autoimmun Rev. 2019 Mar;18(3):312-314. doi: 10.1016/j.autrev.2018.11.002. Epub 2019 Jan 11.

Authors

Giacomo Emmi¹, Alessandra Bettiol², Boaz Palterer³, Elena Silvestri³, Gianfranco Vitiello³, Paola Parronchi³, Domenico Prisco³

Affiliations

¹ Department of Experimental and Clinical Medicine, University of Firenze, Italy. Electronic address: giacomaci@yahoo.it.
² Department of Experimental and Clinical Medicine, University of Firenze, Italy; Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Firenze, Italy.
³ Department of Experimental and Clinical Medicine, University of Firenze, Italy.

PMID: 30639638
DOI: 10.1016/j.autrev.2018.11.002

No abstract available

Keywords: Antiphospholipid antibodies; B-cells; Belimumab; Hydroxychloroquine; SLE.

Publication types

Letter
Comment

MeSH terms

Antibodies, Antiphospholipid
Antibodies, Monoclonal, Humanized
Antiphospholipid Syndrome*
Glycoproteins
Humans
Hydroxychloroquine
Lupus Erythematosus, Systemic*

Substances

Antibodies, Antiphospholipid
Antibodies, Monoclonal, Humanized
Glycoproteins
Hydroxychloroquine
belimumab